Matriks Biotechnology is a leading medical biotechnology company founded by Prof. Haluk Ataoglu MD, PhD in 2002. With a strong background in Microbiology & Immunology, Prof.

Ataoglu is the academic-turned-founder and CEO of the company. Matriks Biotek is dedicated to conducting research in life sciences and biotechnology, developing innovative products, and offering them globally to improve people's lives. As a trailblazer in the industry, Matriks Biotek® introduced the first ELISA kits for monitoring biological drugs called SHIKARI® in 2008.

These kits enable the measurement of drug levels in patients, allowing for optimal dosing and adjustments if needed. The company's commitment to safe and effective use of biologics extends to proactive monitoring, which also contributes to cost-effectiveness. In response to the pandemic, Matriks Biotek has conducted extensive research and developed CoronaHunter® ELISA kits.

These groundbreaking kits provide real quantitative measurements of immunoglobulin G, A, M, and E antibody concentrations for Covid-19. With 16 different kits available, including unique IgE measuring kits, Matriks Biotek offers accurate and harmonized results for Covid-19 testing. Matriks Biotek prides itself on its strong focus on R&D, allocating half of its revenue to ongoing research.

The company maintains the highest standards of quality and operates under the ISO 13485:2016 quality management system. With a wide range of products and a commitment to global export, Matriks Biotek is a trusted partner for pharmaceutical companies and researchers worldwide